Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 9/20 | 0.58 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780272 | 0.89 | CA2 (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL874437 | 0.85 | AR (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16295051 | 0.83 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20743498 | 0.81 | NQO1 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4952656 | 0.80 | CA2 (0.58) | CA12CA1CA2CA9MMP9 | |
| SCHEMBL24041902 | 0.79 | MAOB (0.48) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11445546 | 0.77 | CYP1A2 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7420399 | 0.77 | CA2 (0.47) | CA12CA1CA2CA9MMP2 | |
| SCHEMBL5606537 | 0.77 | MAOB (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5937187 | 0.77 | APLNR (0.59) | CA12CA1CA2CA9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111501-A1 | DERIVATIVES OF IMIDAZO [4, 5-D] PYRIDAZINE AND THEIR USE AS ANTI-VIRAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226398-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | MAVS, SARS1, HAVCR2 | CA12 495/4885CA1 1680/4885CA2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.